{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}],"title":"Partial response"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Complete response"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Stable disease"},{"measurements":[{"groupId":"OG000","value":"0"}],"title":"Progressive disease"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"}],"units":"Participants"}],"description":"Number of patients with complete response, partial response, stable disease, or progressive disease. Assessed via Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.0): Complete Response (CR), Disappearance of all target lesions; Partial Response (PR), \\>=30% decrease in the sum of the longest diameter of target lesions; Overall Response (OR) = CR + PR. Measured via conventional CT and MRI","groups":[{"description":"Patients receive erlotinib hydrochloride orally or via gastrostomy tube once daily in weeks 1-9 and then for 2 years following completion of radiation therapy. Beginning on day 1 of week 2, patients undergo radiation therapy once daily, 5 times a week, for 5-7 weeks. Treatment continues in the absence of disease progression or unacceptable toxicity.","id":"OG000","title":"Arm I"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"One patient progressed while study was still active, study closed before follow up completed for second participant and therefore was not evaluable.","reportingStatus":"POSTED","timeFrame":"1 year and 10 months following study start","title":"Objective Response Rate","type":"SECONDARY","unitOfMeasure":"Participants"}